4/16
11:08 am
roiv
Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.
Low
Report
Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.
4/15
02:43 pm
roiv
Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]
Low
Report
Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]
4/9
07:28 am
roiv
Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]
Low
Report
Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]
4/3
07:41 am
roiv
Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]
Medium
Report
Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]
4/2
04:38 pm
roiv
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]
Low
Report
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]
4/2
04:38 pm
roiv
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]
Low
Report
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]
4/2
10:29 am
roiv
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]
Low
Report
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]
4/2
06:52 am
roiv
Immunovant falls on late-stage trial setback for TED therapy [Seeking Alpha]
Medium
Report
Immunovant falls on late-stage trial setback for TED therapy [Seeking Alpha]
4/2
05:00 am
roiv
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Low
Report
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
4/2
05:00 am
roiv
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Low
Report
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
3/28
03:00 pm
roiv
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Low
Report
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
3/20
09:00 am
roiv
Roivant Sciences (ROIV) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $35.00 price target on the stock.
Low
Report
Roivant Sciences (ROIV) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $35.00 price target on the stock.
3/20
08:29 am
roiv
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD [Yahoo! Finance]
Low
Report
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD [Yahoo! Finance]
3/4
03:32 pm
roiv
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength [Yahoo! Finance]
Low
Report
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength [Yahoo! Finance]
3/4
09:03 am
roiv
Roivant Sciences (ROIV) had its "buy" rating reaffirmed by TD Cowen.
Low
Report
Roivant Sciences (ROIV) had its "buy" rating reaffirmed by TD Cowen.
3/4
08:39 am
roiv
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance]
Low
Report
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance]
3/4
08:38 am
roiv
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance Canada]
Low
Report
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance Canada]
3/4
08:00 am
roiv
Roivant Sciences (ROIV) had its price target raised by HC Wainwright from $33.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences (ROIV) had its price target raised by HC Wainwright from $33.00 to $34.00. They now have a "buy" rating on the stock.
3/4
05:34 am
roiv
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders [Yahoo! Finance]
Medium
Report
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders [Yahoo! Finance]
3/3
04:36 pm
roiv
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute [Yahoo! Finance]
Medium
Report
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute [Yahoo! Finance]
3/3
04:34 pm
roiv
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna [Yahoo! Finance]
Medium
Report
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna [Yahoo! Finance]
3/3
04:15 pm
roiv
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Medium
Report
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
3/3
02:12 pm
roiv
Roivant Sciences (ROIV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Roivant Sciences (ROIV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/3
07:00 am
roiv
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Low
Report
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
2/10
06:52 pm
roiv
Roivant Sciences (NASDAQ:ROIV) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d)" rating.
Low
Report
Roivant Sciences (NASDAQ:ROIV) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d)" rating.